News
New Peer-Reviewed Paper on MiCheck® Prostate
Minomic is pleased to announce the publication of the company’s latest research paper supporting the utilisation of MiCheck® Prostate as an aid to diagnosing clinically significant prostate cancer. It is clear there is strong clinical need to identify those patients...
Dr Brad Walsh’s interview on Australia’s leading business and finance streaming service AusBiz
Last Thursday Dr Brad Walsh was interviewed on Australia's leading business and finance streaming service, AusBiz by renowned TV personality David Koch about Minomic’s technology and future plans as a fitting end to Prostate Cancer Awareness Month. You can view it...
Minomic International Ltd Receives Reimbursement for MiCheck® Prostate in the USA
Thursday 28 September, Sydney, Australia Sydney-based biotech Minomic International Ltd is delighted to announce that the company’s ground-breaking test for prostate cancer, MiCheck® Prostate, has received its first reimbursement in the United States from the Centres...
Minomic’s presentation at the 23rd Asia-Pacific Prostate Cancer Conference
We are proud to be presenting at the 23rd Asia-Pacific Prostate Cancer Conference, one of the largest comprehensive prostate cancer meetings in the world, that is being held between 18 - 20 August 2023 in Cairns. Minomic CEO, Dr Brad Walsh will present a poster...
Minomic’s participation at the AUA 2023
The Minomic International Ltd team was delighted to share our new findings on the application of MiCheck® Prostate with MRI-derived data at the poster presentation session at the American Urological Association's 2023 Annual Meeting on April 28 2023 in Chicago. It was...
Minomic joins Macquarie University at the DeepTech Incubator
We are pleased to announce that Minomic International Ltd has officially joined Macquarie University at the DeepTech Incubator. “We are excited to continue our partnership with the Macquarie University Incubator, working with them to continue growing Minomic to its...